Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Shrink Nanotechnologies Forms Audit Committee Led by Independent Chairman Victor Hollander, CPA

Abstract:
Shrink Nanotechnologies, Inc. ("Shrink") (INKN.D 0.84, +0.58, +228.25%) (OTCBB:INKN), an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that its Board of Directors has established an Audit Committee and appointed Victor A. Hollander, CPA as its chairman. Mr. Hollander will be joined on the Shrink Audit Committee by Marshall Khine, also a member of the Shrink Board of Directors. The addition of Mr. Hollander brings the total number of Shrink Board of Directors members to 5.

Shrink Nanotechnologies Forms Audit Committee Led by Independent Chairman Victor Hollander, CPA

Carlsbad, CA | Posted on April 22nd, 2010

With nearly 50 years of experience working with privately-held and public SEC reporting companies on a global basis, Mr. Hollander has served on various securities, ethics, accounting and auditing committees. He is currently Director and Audit Committee Chairman of Micro Imaging Technology, Inc. of Laguna Hills, CA, and Director of Fuqi International, Inc. of Shenzhen, Guangdong, China. Mr. Hollander is licensed to practice public accounting in the State of California since 1958.

"The goal of our independent Audit Committee is to provide high quality consistent transparency to the financial community as we execute on our core businesses," said Mark L. Baum, CEO of Shrink Nanotechnologies, Inc. Baum added, "Coupled with our Code of Ethics which has been in place since 2006, our Audit Committee led by Mr. Hollander will ensure Shrink adopts the best practices of corporate governance. We also will look to his guidance in selecting additional independent members to join our Audit Committee, which we expect to announce in the near future."

Mr. Hollander began his career at Joseph S. Herbert & Co., a prominent New York accounting firm in 1954. He went on to establish and serve as partner of the Los Angeles office of New York-based accounting firm Brout & Company. In 1978, he co-founded Hollander, Gilbert & Co, specializing in capital raises and merger and acquisitions. In 2002, Mr. Hollander joined Weinberg & Company as Managing Director of its West Coast Group. He retired from the firm in January 2007 and currently performs SEC consulting services. Mr. Hollander received a BA in Accounting from the California State University, Los Angeles.

To learn more about Shrink Nanotechnologies, Inc. or to download the most up-to-date shareholder kit, please visit at www.shrinknano.com and www.shrinksolar.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed a review or audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Shrink's ability to obtain additional financing and to build and develop markets for Shrink's technologies and products. Shrink undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Shrink's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Shrink's success are more fully disclosed in Shrink's most recent public filings with the U.S. Securities and Exchange Commission.


####

About Shrink Nanotechnologies
Shrink is a first of its kind FIGA(TM) organization. FIGA companies bring together diverse contributions from leaders in the worlds of finance, industry, government and academia. Shrink's solutions, including its diverse polymer substrates, nano-devices and biotech research tools, among others, are designed to be ultra-functional and mechanically superior in the solar energy, environmental detection, stem cell research tools and biotechnology device markets. The Company's products are based on a pre-stressed plastic called NanoShrink(TM), and on a patent-pending manufacturing process called the ShrinkChip Manufacturing Solution(TM). Shrink's unique materials and manufacturing solution represents a new paradigm in the rapid design, low-cost fabrication and manufacture of nano-scale devices for numerous significant markets.

For more information, please click here

Contacts:
for Shrink Nanotechnologies
Mark L. Baum, Esq.
760-804-8844 x205

Copyright © Shrink Nanotechnologies

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project